TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11276031

Group type: EXPERIMENTAL
Intervention: Model for analysis of informatively censored data based on a two-stage linear random effects model.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximum likelihood estimation using the EM algorithm.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensitivity analyses and simulations.
Number of subjects: 0
Study: 9462187

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) for 72 hours
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5‐1 mg/kg/day intravenous for 6 days)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both inhaled NO and dexamethasone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional management (control group)
Number of subjects: 42
Study: 7949804

Group type: EXPERIMENTAL
Intervention: 0.5 IU/kg/week of recombinant human growth hormone for over one year
Number of subjects: 28

Group type: COMPARATOR
Intervention: None (untreated)
Number of subjects: 28
Study: 2896219

Group type: EXPERIMENTAL
Intervention: Liquid bismuth subsalicylate (BSS)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Two-vial system (Enteric Plus medium and polyvinyl alcohol fixative)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Three-vial system (buffered glycerol saline, Cary‐Blair medium with campylobacter antibodies, and polyvinyl alcohol fixative)
Number of subjects: 245
Study: 31299951

Group type: EXPERIMENTAL
Intervention: Collagen synthesis neoepitopes PRO-C3
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Collagen synthesis neoepitope PRO-C6
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Collagen degradation markers C1M
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Collagen degradation markers C3M
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Collagen degradation markers C6M
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Collagen degradation markers CRPM
Number of subjects: 145
Study: 28635334

Group type: EXPERIMENTAL
Intervention: Eating at night (NE; meals at 07:00, 19:00, and 01:30 h)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Not eating at night (NEN; meals at 07:00, 09:30, 16:10, and 19:00 h)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Eating at night (NE)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Not eating at night (NEN)
Number of subjects: 11
Study: 26390793

Group type: EXPERIMENTAL
Intervention: Big Bag IOL
Number of subjects: 127

Group type: COMPARATOR
Intervention: Akreos Adapt IOL
Number of subjects: 127
Study: 23988010

Group type: EXPERIMENTAL
Intervention: Moderate alcohol intake (5 to 15 g/day)
Number of subjects: 5505

Group type: EXPERIMENTAL
Intervention: Wine consumption (2 to 7 drinks/week)
Number of subjects: 5505

Group type: COMPARATOR
Intervention: Heavy alcohol consumption
Number of subjects: 5505
Study: 21430250

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus casei Shirota (LcS) supplementation (1.95 × 10(10) CFU LcS/d)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (similar milk drink without probiotic additive)
Number of subjects: 68
Study: 19023276

Group type: EXPERIMENTAL
Intervention: met-met genotype
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: val-met genotype
Number of subjects: 839

Group type: COMPARATOR
Intervention: val-val genotype
Number of subjects: 839
Study: 17159759

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.25 microg kg(‐1)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.50 microg kg(‐1)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Alfentanil 15 microg kg(‐1)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Alfentanil 20 microg kg(‐1)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Lidocaine 1 mL of 1% (10 mg) added to 100 mg of propofol
Number of subjects: 306

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 306
Study: 15480327

Group type: EXPERIMENTAL
Intervention: HDM-impermeable covers
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo covers
Number of subjects: 52
Study: 12404675

Group type: EXPERIMENTAL
Intervention: Tianeptine (37.5 mg/day)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 178

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 178
Study: 9593759

Group type: EXPERIMENTAL
Intervention: C-peptide (8 pmol kg-1 min-1)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline solution (154 mmol liter-1 NaCl)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 19
Study: 8005273

Group type: EXPERIMENTAL
Intervention: Endometrial priming with oral micronized E2, 4 mg/d for 14 days; Progesterone replacement IM P in oil, 50 mg/d for 14 days.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group continued the same E2 regimen during the luteal phase.
Number of subjects: 14
Study: 2680288

Group type: EXPERIMENTAL
Intervention: Bezafibrate (200 mg twice or 3 times a day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Probucol (500 mg twice a day)
Number of subjects: 60
Study: 1096704

Group type: EXPERIMENTAL
Intervention: sulfamethizole, nitrofurantoin, methenamine mandelate
Number of subjects: 249

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 249
Study: 30898253

Group type: EXPERIMENTAL
Intervention: Sirolimus-coated balloon (SeQuent SCB, 4 μg/mm2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Paclitaxel-coated balloon (SeQuent Please Neo, 3 μg/mm2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 50
Study: 27189694

Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6MP) medication adherence
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Behavioral adherence measures (e.g., electronic monitoring)
Number of subjects: 139
Study: 25996285

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation (women's and men's formula) for 16 weeks
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 116
Study: 23587106

Group type: EXPERIMENTAL
Intervention: Bilateral Robot-Assisted Training (BRT)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Unilateral Robot-Assisted Training (URT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control Treatment (CT)
Number of subjects: 53
Study: 21793690

Group type: EXPERIMENTAL
Intervention: General Psychotherapy (GPT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: General Psychotherapy Minus Clarification (GPT-C)
Number of subjects: 67
Study: 19372653

Group type: EXPERIMENTAL
Intervention: Terutroban 30 mg/day
Number of subjects: 18000

Group type: COMPARATOR
Intervention: Aspirin 100 mg/day
Number of subjects: 18000
Study: 17448768

Group type: EXPERIMENTAL
Intervention: Laparoscopic pyloromyotomy (LP)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Open circumumbilical pyloromyotomy (OP)
Number of subjects: 102
Study: 15353532

Group type: EXPERIMENTAL
Intervention: Galantamine hydrobromide 2.5 mg
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Galantamine hydrobromide 5.0 mg
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Galantamine hydrobromide 7.5 mg
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Galantamine hydrobromide 10 mg
Number of subjects: 434

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 434
Study: 11500334

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP), 336 microg/d
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo inhaler
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 24
Study: 9505743

Group type: EXPERIMENTAL
Intervention: Laryngeal mask anaesthesia
Number of subjects: 15

Group type: COMPARATOR
Intervention: Face mask anaesthesia
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Avoiding nitrous oxide until laryngeal mask insertion
Number of subjects: 15
Study: 8001713

Group type: EXPERIMENTAL
Intervention: Type 2 diabetic patients
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Patients with macroangiopathy and/or microangiopathy
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Hypertensive patients without vascular affection
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Thiobarbituric acid-reactive substances
Number of subjects: 204
Study: 2605069

Group type: EXPERIMENTAL
Intervention: Cimetidine 1600 mg orally before anaesthesia
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo tablets before anaesthesia
Number of subjects: 53
Study: 1099184

Group type: EXPERIMENTAL
Intervention: Early Continuous Negative Pressure (ECNP)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Late Continuous Negative Pressure (LCNP)
Number of subjects: 23
Study: 31424550

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Azithromycin-resistant isolates
Number of subjects: 66
Study: 28823365

Group type: EXPERIMENTAL
Intervention: Fast-track surgery (FT group, n=54)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Conventional process (NFT group, n=74)
Number of subjects: 128
Study: 25615708

Group type: EXPERIMENTAL
Intervention: Storytelling intervention (video created from personal stories)
Number of subjects: 539

Group type: COMPARATOR
Intervention: Personal risk tool intervention (instrument estimating level of personal cancer risk)
Number of subjects: 539
Study: 22921476

Group type: EXPERIMENTAL
Intervention: Buprenorphine/Naloxone (BUP)
Number of subjects: 1269

Group type: COMPARATOR
Intervention: Methadone (MET)
Number of subjects: 1269
Study: 20943714

Group type: EXPERIMENTAL
Intervention: Pedometer-based gait training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional gait training programme (Control)
Number of subjects: 30
Study: 18202589

Group type: EXPERIMENTAL
Intervention: Pueraria mirifica (20, 30, or 50 mg once daily for 24 weeks)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (identical capsules once daily for 24 weeks)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Pueraria mirifica and Placebo
Number of subjects: 71
Study: 16862360

Group type: EXPERIMENTAL
Intervention: Enameloplasty sealant technique (EST)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Cup-shaped brush sealant technique (CST)
Number of subjects: 162
Study: 16151033

Group type: EXPERIMENTAL
Intervention: Clopidogrel with aspirin (C+ASA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Aspirin alone (ASA)
Number of subjects: 70
Study: 12830063

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 157
Study: 10524785

Group type: EXPERIMENTAL
Intervention: Omafilcon A lenses (Proclear; Biocompatibles)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Etafilcon A lenses (Acuvue; Vistakon)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Symptomatic group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Asymptomatic group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Symptomatic hydrogel contact lens wearers
Number of subjects: 40
Study: 7741782

Group type: EXPERIMENTAL
Intervention: Amoxicillin (250 mg) plus bromhexine (8 mg) (Drug AB)
Number of subjects: 392
Study: 2290329

Group type: EXPERIMENTAL
Intervention: fenigidin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: cordafen
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: corinfar
Number of subjects: 14
Study: 7028298

Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 131
Study: 31919692

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 77911

Group type: EXPERIMENTAL
Intervention: Current HRT usage
Number of subjects: 77911
Study: 29802080

Group type: EXPERIMENTAL
Intervention: Consecutive dual-task training (n = 65)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Integrated dual-task training (n = 56)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control period (two baseline measurements)
Number of subjects: 121
Study: 26443067

Group type: EXPERIMENTAL
Intervention: Cord group (Ultrapack, SilTrax AS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cordless group (Expasyl, Traxodent Hemodent paste)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All groups (Cord and Cordless)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Expasyl (Cordless)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cord group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cord and Cordless techniques
Number of subjects: 40
Study: 24154820

Group type: EXPERIMENTAL
Intervention: Prosure (specific supplement enriched with n-3 polyunsaturated fatty acids, fiber, proteins, and electrolytes)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard-Isosource (standard supplement)
Number of subjects: 26
Study: 23829674

Group type: EXPERIMENTAL
Intervention: Onsite heart failure service
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard care without onsite heart failure service
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Interventions for heart failure
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Involvement in healthcare decisions
Number of subjects: 33
Study: 20410414

Group type: EXPERIMENTAL
Intervention: Virtual CT sonography
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional sonography
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Nodule size, echo pattern, and location
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Nodules 10 mm in diameter or smaller
Number of subjects: 59
Study: 18523220

Group type: EXPERIMENTAL
Intervention: Family history of colorectal cancer (1 or more affected first-degree relatives)
Number of subjects: 1087

Group type: EXPERIMENTAL
Intervention: Family history of colorectal cancer (1 affected first-degree relative)
Number of subjects: 1087

Group type: EXPERIMENTAL
Intervention: Family history of colorectal cancer (2 or more affected first-degree relatives)
Number of subjects: 1087

Group type: COMPARATOR
Intervention: No family history of colorectal cancer
Number of subjects: 1087

Group type: EXPERIMENTAL
Intervention: Family history of colorectal cancer
Number of subjects: 1087
Study: 16564279

Group type: EXPERIMENTAL
Intervention: Mini-extracorporeal circulation (MECC) system (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard cardiopulmonary bypass (group B)
Number of subjects: 60
Study: 12673176

Group type: EXPERIMENTAL
Intervention: I-123 MIBG imaging and HRV analysis
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combination of I‐123 MIBG heart‐mediastinal ratio and HRV 5‐minute low‐frequency variables
Number of subjects: 17
Study: 10911790

Group type: EXPERIMENTAL
Intervention: Curved needle technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional straight needle
Number of subjects: 0
Study: 9387758

Group type: EXPERIMENTAL
Intervention: Combined group (RAG I and II plus whole embryo extract)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Discombined group (RAG I and II only)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Experimental study in animal models (treated group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (animal models)
Number of subjects: 30
Study: 1401688

Group type: EXPERIMENTAL
Intervention: Geriatric evaluation and management program
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 200
Study: 3881211

Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 181

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 181
Study: 30694099

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus plantarum IS-10506)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Zinc
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Probiotic and Zinc
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 29893604

Group type: EXPERIMENTAL
Intervention: Hip and core-focused rehabilitation (n = 111)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Knee-focused rehabilitation (n = 88)
Number of subjects: 199
Study: 27179988

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg loading dose followed by 81 mg/d)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 390
Study: 25122186

Group type: EXPERIMENTAL
Intervention: Left ventricular hypertrophy
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: Elevated left ventricular filling pressure (E/E')
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: Higher pulmonary artery pressure (tricuspid regurgitation velocity)
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: Composite outcome of cardiovascular death, heart failure hospitalization, or aborted cardiac arrest
Number of subjects: 935
Study: 23168146

Group type: EXPERIMENTAL
Intervention: Escitalopram (Group A, Beck positive)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (Group B, Beck positive)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Escitalopram (Group C, Beck negative)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (Group D, Beck negative)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C, D)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Escitalopram (Group A)
Number of subjects: 120
Study: 20592433

Group type: EXPERIMENTAL
Intervention: Mental health literacy intervention
Number of subjects: 909

Group type: COMPARATOR
Intervention: Folic acid (400 mcg/d) + vitamin B12 (100 mcg/d)
Number of subjects: 909

Group type: COMPARATOR
Intervention: Physical activity promotion
Number of subjects: 909

Group type: COMPARATOR
Intervention: Nutrition promotion control
Number of subjects: 909
Study: 18588848

Group type: EXPERIMENTAL
Intervention: Misoprostol 400 microg administered vaginally twice, 6 and 12 hours before hysteroscopy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (hexetidine pill) administered vaginally twice, 6 and 12 hours before hysteroscopy
Number of subjects: 60
Study: 16087019

Group type: EXPERIMENTAL
Intervention: Controlled temperature radiofrequency (RF)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Injection snoreplasty (IS)
Number of subjects: 70
Study: 12544159

Group type: EXPERIMENTAL
Intervention: Home interferential current therapy (IFC)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo (no current)
Number of subjects: 87
Study: 10479130

Group type: EXPERIMENTAL
Intervention: Protease inhibitor-containing triple therapy for 2 years
Number of subjects: 19
Study: 7488802

Group type: EXPERIMENTAL
Intervention: ECMO
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Long-term outcome
Number of subjects: 28
Study: 1891022

Group type: EXPERIMENTAL
Intervention: Controlled-release aspirin (75 mg, releasing 10 mg per hour)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate-release aspirin (162.5 mg loading dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate-release aspirin (75 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled-release aspirin (75 mg)
Number of subjects: 0
Study: 6215855

Group type: EXPERIMENTAL
Intervention: Bound niacin (BN) - 35 mg niacin
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Alkali-treated bound niacin (ABN) - 24 mg pure nicotinic acid
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Nicotinic acid - 24 mg
Number of subjects: 3
Study: 28847468

Group type: EXPERIMENTAL
Intervention: slow‐release melatonin at a dose of 3mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: oral placebo
Number of subjects: 100
Study: 25318574

Group type: EXPERIMENTAL
Intervention: Ahmed glaucoma valve (AGV)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 24 μm Gold Micro‐Shunt (GMS)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 48 μm Gold Micro‐Shunt (GMS)
Number of subjects: 29
Study: 24477842

Group type: COMPARATOR
Intervention: Fluoride-free toothpaste (Control)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Toothpaste A (0.4% SnF2, Solidox)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Toothpaste B (0.454% SnF2, Oral-B(®))
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: SnF2 solution (0.4%, 1,000 ppm F)
Number of subjects: 16
Study: 23216685

Group type: EXPERIMENTAL
Intervention: CareWell-primary care program
Number of subjects: 600

Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 600
Study: 20363764

Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel loading 4-8 hours before PCI
Number of subjects: 503

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 503
Study: 17435356

Group type: COMPARATOR
Intervention: Shinrin-yoku (forest atmosphere)
Number of subjects: 12
Study: 16116130

Group type: EXPERIMENTAL
Intervention: Amino acid drink containing l-tryptophan
Number of subjects: 76

Group type: COMPARATOR
Intervention: Amino acid drink omitting l-tryptophan
Number of subjects: 76
Study: 12099919

Group type: EXPERIMENTAL
Intervention: Treatment in a stroke unit (SU)
Number of subjects: 477

Group type: COMPARATOR
Intervention: General medical wards (GMWs)
Number of subjects: 477

Group type: COMPARATOR
Intervention: Minor stroke (SSS-score >30)
Number of subjects: 477

Group type: COMPARATOR
Intervention: Severe stroke
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: SSS-score below 30
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 477
Study: 10574417

Group type: EXPERIMENTAL
Intervention: Pravastatin (n = 32)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (n = 25)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Comparison of Pravastatin vs Placebo
Number of subjects: 57
Study: 8918516

Group type: EXPERIMENTAL
Intervention: Al(OH)3 (one tablet three times a day, about 302 mg aluminium day‐1) for 3 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (20 patients receiving no Al‐containing agents)
Number of subjects: 70
Study: 1907681

Group type: EXPERIMENTAL
Intervention: Vivonex TEN (unflavored)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ensure
Number of subjects: 10

Group type: COMPARATOR
Intervention: phenytoin suspension alone
Number of subjects: 10
Study: 6440313

Group type: EXPERIMENTAL
Intervention: Gliclazide 40 mg
Number of subjects: 277

Group type: COMPARATOR
Intervention: Glibenclamide 2.5 mg
Number of subjects: 277